A groundbreaking interdisciplinary investigation emanating from Nagoya University in Japan has brought to light a significant and previously underestimated risk associated with the routine application of certain eye care products. The comprehensive study definitively establishes that petrolatum-based ophthalmic ointments can critically compromise the structural integrity of a widely utilized medical device for glaucoma management, the PRESERFLO MicroShunt, potentially leading to swelling and, in severe instances, device rupture. This critical finding, substantiated through a meticulous combination of real-world patient observations and rigorous laboratory experimentation, has profound implications for post-operative care protocols in the more than 60 countries where this particular glaucoma implant is currently employed.
Glaucoma stands as a formidable global health challenge, affecting an estimated 76 million individuals worldwide. This chronic, progressive ocular disease is characterized by damage to the optic nerve, the vital conduit transmitting visual information from the eye to the brain. Often, though not exclusively, the condition arises from an elevated intraocular pressure (IOP) resulting from impaired drainage of aqueous humor, the fluid that nourishes the eye’s internal structures. Left untreated, persistently high IOP can lead to irreversible vision loss and, ultimately, blindness. While various forms of glaucoma exist, primary open-angle glaucoma is the most prevalent, developing gradually without early warning signs, making routine eye examinations crucial for timely diagnosis.
For patients whose intraocular pressure remains inadequately controlled by medications or laser therapies, surgical interventions become necessary. The PRESERFLO MicroShunt represents a significant advancement in the surgical treatment landscape, categorized under Minimally Invasive Glaucoma Surgery (MIGS). This innovative device, a tiny filtration implant, is surgically positioned to create an alternative outflow pathway for the excess aqueous humor from the anterior chamber of the eye into the subconjunctival space, thereby reducing IOP. Its appeal lies in its streamlined surgical procedure, often associated with a quicker recovery time, fewer post-operative complications, and a reduced reliance on long-term glaucoma medications compared to more traditional, invasive procedures like trabeculectomy. These benefits have contributed to its widespread adoption by ophthalmologists seeking effective yet less burdensome solutions for their patients.
The PRESERFLO MicroShunt’s design leverages a sophisticated material science approach. It is fabricated from a styrenic thermoplastic elastomer, specifically a polystyrene-block-polyisobutylene-block-polystyrene (SIBS) block polymer. This choice of material is deliberate, offering a combination of flexibility, excellent biocompatibility within the delicate ocular environment, and a reduced propensity for eliciting inflammatory responses or scarring—factors critical for long-term device success. However, the very chemical properties that bestow these advantages also introduce an unforeseen vulnerability. The SIBS polymer exhibits a strong affinity for hydrocarbon- and oil-based substances. This molecular attraction means that when the implant comes into direct contact with such compounds, particularly the petroleum jelly constituents found in many common eye ointments, these oil components can readily permeate and become absorbed into the polymer matrix of the device.
The absorption of these lipophilic compounds triggers a cascade of detrimental physical changes within the implant. As the oil components infiltrate the SIBS material, they disrupt its molecular structure, causing the polymer chains to swell and expand. This volumetric increase leads to a noticeable change in the device’s shape and a significant degradation of its mechanical strength. What was once a resilient and precisely engineered device becomes compromised, potentially weakening its structural integrity and impairing its functionality.
Despite the inherent material sensitivity, a critical gap in clinical practice appears to exist. The manufacturer’s instructions for use (IFU) for the MicroShunt explicitly caution against direct contact with petrolatum-based materials, specifying that "the MicroShunt should not be subjected to direct contact with petrolatum-based (i.e., petrolatum jelly) materials, such as ointments and dispersions." Regrettably, this crucial guidance has not consistently translated into widespread clinical awareness or adherence. Ophthalmologists and their surgical teams, accustomed to using petrolatum-based ointments as a standard post-operative lubricant and protective barrier, may inadvertently expose the implant to this damaging substance. This oversight underscores a broader challenge in medicine: ensuring that detailed material science considerations are fully integrated into routine clinical protocols. Dr. Ryo Tomita, an ophthalmologist and Assistant Professor at Nagoya University Graduate School of Medicine and the study’s lead author, underscored the gravity of this issue: "I observed a rupture in a swollen MicroShunt during surgery. These swollen devices can be structurally fragile. Increasing awareness among clinicians about this specific risk is paramount to preventing similar complications."
Driven by these clinical observations, Professor Tomita initiated a collaborative research effort, bridging the typically distinct fields of medicine and engineering. He partnered with Assistant Professor Taiga Inooka and Associate Professor Kenya Yuki from Nagoya University Hospital and the Graduate School of Medicine, alongside Dr. Takato Kajita and Junior Associate Professor Atsushi Noro from the Graduate Graduate School of Engineering. This interdisciplinary team embarked on a mission to systematically investigate the precise mechanisms by which petrolatum-based eye ointments affect the MicroShunt. Their findings, published in the esteemed journal Graefe’s Archive for Clinical and Experimental Ophthalmology, provide compelling evidence of the device’s vulnerability.
The medical component of the study involved a meticulous analysis of seven glaucoma patients who had previously received MicroShunt implants that were subsequently explanted for various clinical reasons. This clinical retrospective review revealed a striking correlation between ointment exposure and device damage. In three distinct cases, the MicroShunt had become exposed outside the conjunctiva—the transparent membrane covering the white part of the eye—and these patients had received post-operative treatment with petrolatum-based eye ointments. Alarmingly, all three of these explanted devices exhibited pronounced swelling, and two of them were found to have completely ruptured. Conversely, in three other cases where the MicroShunt remained fully covered by the conjunctiva and no petrolatum-based ointment was used, the implants maintained their original, intact structural integrity. A particularly illuminating case involved an exposed MicroShunt where, crucially, no petrolatum-based ointment had been applied. In this instance, the implant did not swell, providing compelling clinical evidence that direct contact with the ointment, rather than mere conjunctival exposure, is the primary causative factor for the observed swelling and subsequent structural degradation.
To further elucidate the underlying mechanism, the engineering team conducted a series of controlled laboratory experiments. Unused, pristine MicroShunt devices were subjected to simulated clinical conditions by immersing them directly in petrolatum-based eye ointment. Microscopic analysis of these devices demonstrated a remarkably rapid and significant expansion. Within just 24 hours of continuous exposure, the outer diameter of the MicroShunt had increased to 1.44 times its initial dimension, while the fin-like components, critical for anchoring and fluid flow, widened to 1.29 times their original size. Chemical analysis, employing gravimetric methods, further revealed the extent of absorption: after 24 hours of immersion, the oil components constituted approximately 45% of the MicroShunt’s total weight. This absorption escalated over time, reaching a staggering 73% of the device’s weight after three months of sustained exposure. These laboratory results unequivocally confirmed that the observed swelling and structural compromise are directly attributable to the robust absorption of oil-based components from the petrolatum ointment into the SIBS polymer material.
The implications of these findings are far-reaching and necessitate an immediate reassessment of post-operative care protocols for patients undergoing MicroShunt implantation. The research team strongly advises ophthalmologists and other clinicians to meticulously avoid the use of petrolatum-based eye ointments in patients who have received a MicroShunt, especially in scenarios where the device may be exposed outside the conjunctiva. Alternative, non-petrolatum-based lubricants or protective measures should be considered and integrated into standard practice.
Beyond immediate clinical adjustments, this study highlights the critical importance of a holistic understanding of medical device materials and their potential interactions within the complex physiological and therapeutic environment. As Junior Associate Professor Atsushi Noro from the Graduate School of Engineering aptly articulated, "Our study found that commonly used medical materials can cause unexpected complications if their chemical properties and usage environments are not fully understood. From both medical and engineering perspectives, we emphasize the importance of understanding the chemical properties of medical materials and appropriately managing their usage environments." This emphasizes a broader call for vigilance in material selection and interaction analysis throughout the lifecycle of medical devices, from design and development to clinical application. Furthermore, the researchers suggest that future studies are essential to determine whether the observed swelling, even in the absence of outright rupture, might subtly impair the long-term performance and efficacy of the implant in managing intraocular pressure, thereby affecting patient outcomes over time. This seminal work from Nagoya University serves as a vital reminder that even routine medical practices warrant continuous scrutiny through the lens of advanced scientific inquiry to ensure optimal patient safety and device longevity.
About the Author
